Cargando…

Rationale for Surrogate Endpoints and Conditional Marketing Authorization of New Therapies for Kidney Transplantation

Conditional marketing authorization (CMA) facilitates timely access to new drugs for illnesses with unmet clinical needs, such as late graft failure after kidney transplantation. Late graft failure remains a serious, burdensome, and life-threatening condition for recipients. This article has been de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naesens, Maarten, Loupy, Alexandre, Hilbrands, Luuk, Oberbauer, Rainer, Bellini, Maria Irene, Glotz, Denis, Grinyó, Josep, Heemann, Uwe, Jochmans, Ina, Pengel, Liset, Reinders, Marlies, Schneeberger, Stefan, Budde, Klemens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Health Archive
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163307/ https://www.ncbi.nlm.nih.gov/pubmed/35669977 http://dx.doi.org/10.3389/ti.2022.10137

Ejemplares similares

Surrogate Endpoints for Late Kidney Transplantation Failure
por: Naesens, Maarten, et al.
Publicado: (2022)

Allograft Function as Endpoint for Clinical Trials in Kidney Transplantation
por: Hilbrands, Luuk, et al.
Publicado: (2022)

Proposed Definitions of T Cell-Mediated Rejection and Tubulointerstitial Inflammation as Clinical Trial Endpoints in Kidney Transplantation
por: Seron, Daniel, et al.
Publicado: (2022)

Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial Endpoint in Kidney Transplantation
por: Roufosse, Candice, et al.
Publicado: (2022)

Patient-Reported Outcomes as Endpoints in Clinical Trials of Kidney Transplantation Interventions
por: Tong, Allison, et al.
Publicado: (2022)

Alloimmune Risk Stratification for Kidney Transplant Rejection
por: Bestard, Oriol, et al.
Publicado: (2022)

Redefining Risk Stratification and Endpoints for Clinical Trials in Kidney Transplantation: Rationale and Methodology of Proposals Submitted to the European Medicines Agency by the European Society for Organ Transplantation
por: Naesens, Maarten, et al.
Publicado: (2022)

European Guideline for the Management of Kidney Transplant Patients With HLA Antibodies: By the European Society for Organ Transplantation Working Group
por: Mamode, Nizam, et al.
Publicado: (2022)

Evolution of the Definition of Rejection in Kidney Transplantation and Its Use as an Endpoint in Clinical Trials
por: Becker, Jan Ulrich, et al.
Publicado: (2022)

Editorial: Transplant International Goes for GOLD!
por: Bellini, Maria Irene, et al.
Publicado: (2022)

Editorial: Rubies for ESOT!
por: Berney, Thierry, et al.
Publicado: (2022)

Reflecting on an Intense Year for Transplant International
por: Berney, Thierry, et al.
Publicado: (2022)

Xenotransplantion: Defeating the “Shumway Curse” An Interview With Drs. Bartley Griffith, Jayme Locke, Robert Montgomery, and Bruno Reichart
por: Berney, Thierry, et al.
Publicado: (2022)

Qualifying a Novel Clinical Trial Endpoint (iBOX) Predictive of Long-Term Kidney Transplant Outcomes
por: Klein, Amanda, et al.
Publicado: (2023)

Sense and Sensibilities of Organ Perfusion as a Kidney and Liver Viability Assessment Platform
por: Verstraeten, Laurence, et al.
Publicado: (2022)

ESOT Consensus Platform for Organ Transplantation: Setting the Stage for a Rigorous, Regularly Updated Development Process
por: Cillo, Umberto, et al.
Publicado: (2022)

Surrogate endpoints.
por: Ellenberg, S. S.
Publicado: (1993)

Eliminating Race From eGFR Calculations: Impact on Living Donor Programs
por: Bellini, Maria Irene, et al.
Publicado: (2022)

Back to the Future With Co-Stimulation Blockade
por: Flechner, Stuart M., et al.
Publicado: (2023)

Is Preemptive Kidney Transplantation Associated With Improved Outcomes when Compared to Non-preemptive Kidney Transplantation in Children? A Systematic Review and Meta-Analysis
por: Rana Magar, Reshma, et al.
Publicado: (2022)

The evaluation of surrogate endpoints
por: Burzykowski, Tomasz, et al.
Publicado: (2005)

Surrogate Endpoints in Medicine
por: Srivastava, Sudhir, et al.
Publicado: (2002)

European Society for Organ Transplantation (ESOT)-TLJ 3.0 Consensus on Histopathological Analysis of Pre-Implantation Donor Kidney Biopsy: Redefining the Role in the Process of Graft Assessment
por: Zaza, Gianluigi, et al.
Publicado: (2023)

The Clinical Utility of Post-Transplant Monitoring of Donor-Specific Antibodies in Stable Renal Transplant Recipients: A Consensus Report With Guideline Statements for Clinical Practice
por: van den Broek, Dennis A. J., et al.
Publicado: (2023)

Relinquishing Anonymity in Living Donor Kidney Transplantation: Lessons Learned From the UK Policy for Anonymous Donors
por: Pronk, Mathilde C., et al.
Publicado: (2022)

Embracing the Wisdom of Ancient Greece in the Era of Personalized Medicine—Uncertainty, Probabilistic Reasoning, and Democratic Consensus
por: Naesens, Maarten
Publicado: (2023)

Can We Predict Graft Intolerance Syndrome After Kidney Transplant Failure? External Validation of a Previously Developed Model
por: Bunthof, Kim, et al.
Publicado: (2023)

Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in de novo Kidney Transplant Patients Across Europe
por: Budde, Klemens, et al.
Publicado: (2022)

The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project
por: Sargent, Daniel J., et al.
Publicado: (2017)

Equity, Diversity and Inclusion (EDI) in Organ Transplantation: An ESOT Survey About EDI Within ESOT as an Organization and its Educational Activities, and Transplantation Research and Science
por: Pengel, L. H. M., et al.
Publicado: (2023)

1H-NMR metabolomics-based surrogates to impute common clinical risk factors and endpoints
por: Bizzarri, D., et al.
Publicado: (2021)

The Role of Fc Gamma Receptors in Antibody-Mediated Rejection of Kidney Transplants
por: Delpire, Boris, et al.
Publicado: (2022)

Impact of COVID-19 on Global Kidney Transplantation Service Delivery: Interim Report
por: Papalois, Vassilios, et al.
Publicado: (2022)

Overview of Biomarkers and Surrogate Endpoints in Drug Development
por: Wagner, John A.
Publicado: (2002)

Is critical care ready for an economic surrogate endpoint?
por: Wilcox, M Elizabeth, et al.
Publicado: (2015)

Surrogate endpoints in early prostate cancer research
por: Williams, Scott
Publicado: (2018)

Surrogate endpoints… Uncommon for a common man!
por: Kumar, Ashish
Publicado: (2019)

Peripheral Blood Immune Cell Composition After Autologous MSC Infusion in Kidney Transplantation Recipients
por: Hendriks, Sanne H., et al.
Publicado: (2023)

Need for better reporting of trials with surrogate endpoints: SPIRIT|CONSORT-SURROGATE extensions
por: Ciani, Oriana, et al.
Publicado: (2022)

Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study
por: Aubert, Olivier, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eagpoa4npla74ha340d4tnc771